Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876750 | 1.00 | STAT3 (0.52) | STAT3BACE1LMNAALDH1A1RAB9A | |
| SCHEMBL2536457 | 0.87 | STAT3 (0.54) | STAT3LMNAALDH1A1RAB9APTGS2 | |
| SCHEMBL2536459 | 0.87 | STAT3 (0.54) | STAT3LMNAALDH1A1RAB9APTGS2 | |
| SCHEMBL1013073 | 0.86 | STAT3 (0.53) | STAT3LMNAALDH1A1RAB9APTGS2 | |
| SCHEMBL1013072 | 0.86 | STAT3 (0.53) | STAT3LMNAALDH1A1RAB9APTGS2 | |
| SCHEMBL9377330 | 0.85 | BACE1 (0.49) | STAT3BACE1LMNAALDH1A1RAB9A | |
| SCHEMBL9542727 | 0.85 | BACE1 (0.49) | STAT3BACE1LMNAALDH1A1RAB9A | |
| SCHEMBL5093403 | 0.85 | STAT3 (0.49) | STAT3BACE1LMNAALDH1A1RAB9A | |
| SCHEMBL24358978 | 0.85 | STAT3 (0.52) | STAT3LMNAALDH1A1RAB9APTGS2 | |
| SCHEMBL4956345 | 0.85 | STAT3 (0.52) | STAT3BACE1LMNAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | STAT3 108/4885BACE1 2932/4885LMNA 4536/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | STAT3 102/4885BACE1 3915/4885LMNA 4453/4885 |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | STAT3 3990/4885BACE1 2744/4885LMNA 1920/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | STAT3 110/4885BACE1 3896/4885LMNA 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.